Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery

Description

The purpose if this pilot study is to determine if a perioperative infusion of 0.2% ropivacaine via bilateral T3 paravertebral catheters can decrease the incidence of new onset atrial fibrillation following primary CABG and/or valve surgery and compare a number of secondary outcomes.

Conditions

New Onset Atrial Fibrillation, Anesthesia, Local, Cardiac Disease

Study Overview

Study Details

Study overview

The purpose if this pilot study is to determine if a perioperative infusion of 0.2% ropivacaine via bilateral T3 paravertebral catheters can decrease the incidence of new onset atrial fibrillation following primary CABG and/or valve surgery and compare a number of secondary outcomes.

Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery: A Prospective Randomized Controlled Pilot Trial

Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery

Condition
New Onset Atrial Fibrillation
Intervention / Treatment

-

Contacts and Locations

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * History of atrial fibrillation or flutter
  • * Infective endocarditis
  • * Left ventricular ejection fraction (LVEF) \< 30%
  • * Emergency surgery
  • * Redo surgery
  • * Contraindication to block placement including local anesthetic allergy, bleeding diathesis (physiologic or iatrogenic)
  • * Body mass index \> 35kg/m2
  • * Pregnancy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Minnesota,

James Flaherty, MD, PRINCIPAL_INVESTIGATOR, University of Minnesota

Study Record Dates

2025-07-01